[[{“value”:”
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Cannabis Bioscience International Holdings (CBIH) participated in a DEA hearing on cannabis reclassification in Arlington, Virginia. CEO Dante Picazo presented a 78-page statement supporting the reclassification of cannabis from its current Schedule I status. The company argues that reclassification would bridge science, policy, and opportunity gaps, potentially leading to economic growth, job creation, and advancement in medical research. A final verdict is expected within two to three months following extensive deliberation. CBIH emphasizes that reclassification would enable responsible medical use and resolve long-standing legal ambiguities.
Cannabis Bioscience International Holdings (CBIH) ha partecipato a un’udienza della DEA sulla riclassificazione della cannabis ad Arlington, Virginia. Il CEO Dante Picazo ha presentato una dichiarazione di 78 pagine a sostegno della riclassificazione della cannabis dal suo attuale status di Schedule I. L’azienda sostiene che la riclassificazione potrebbe colmare i divari tra scienza, politica e opportunità, portando potenzialmente a una crescita economica, creazione di posti di lavoro e avanzamenti nella ricerca medica. Un verdetto finale è atteso entro due o tre mesi dopo ampie deliberazioni. CBIH sottolinea che la riclassificazione consentirebbe un utilizzo medico responsabile e risolverebbe ambiguità legali di lunga data.
Cannabis Bioscience International Holdings (CBIH) participó en una audiencia de la DEA sobre la reclasificación de la cannabis en Arlington, Virginia. El CEO Dante Picazo presentó una declaración de 78 páginas apoyando la reclasificación de la cannabis desde su actual estatus de Schedule I. La empresa argumenta que la reclasificación podría cerrar las brechas entre la ciencia, la política y las oportunidades, lo que podría llevar a un crecimiento económico, creación de empleos y avances en la investigación médica. Se espera un veredicto final dentro de dos a tres meses tras una extensa deliberación. CBIH enfatiza que la reclasificación permitiría un uso médico responsable y resolvería ambigüedades legales de larga data.
캔나비스 바이오사이언스 인터내셔널 홀딩스(CBIH)는 버지니아주 알링턴에서 진행된 DEA의 대마초 재분류 청문회에 참여했습니다. CEO 단테 피카조는 대마초의 현재 스케줄 I 상태에서의 재분류를 지지하는 78페이지 분량의 성명을 발표했습니다. 회사는 재분류가 과학, 정책 및 기회 간의 격차를 해소할 수 있으며, 잠재적으로 경제 성장, 일자리 창출 및 의학 연구의 발전으로 이어질 것이라고 주장합니다. 최종 판결은 광범위한 심의 후 두세 달 이내에 예상됩니다. CBIH는 재분류가 책임 있는 의학적 사용을 가능하게 하고 오랜 법적 모호성을 해결할 것이라고 강조합니다.
Cannabis Bioscience International Holdings (CBIH) a participé à une audience de la DEA sur la reclassification du cannabis à Arlington, en Virginie. Le PDG Dante Picazo a présenté une déclaration de 78 pages soutenant la reclassification du cannabis depuis son statut actuel de Schedule I. L’entreprise soutient que cette reclassification pourrait combler les lacunes entre la science, la politique et les opportunités, conduisant potentiellement à une croissance économique, à la création d’emplois et à des avancées dans la recherche médicale. Un verdict final est attendu dans un délai de deux à trois mois suite à de longues délibérations. CBIH souligne que la reclassification permettrait une utilisation médicale responsable et résoudrait des ambiguïtés légales de longue date.
Cannabis Bioscience International Holdings (CBIH) nahm an einer Anhörung der DEA zur Neu-Klassifizierung von Cannabis in Arlington, Virginia, teil. CEO Dante Picazo präsentierte eine 78-seitige Erklärung, die die Neu-Klassifizierung von Cannabis von seinem aktuellen Status als Schedule I unterstützt. Das Unternehmen argumentiert, dass eine Neu-Klassifizierung die Kluften zwischen Wissenschaft, Politik und Chancen überbrücken könnte, was potenziell zu wirtschaftlichem Wachstum, Schaffung von Arbeitsplätzen und Fortschritten in der medizinischen Forschung führen könnte. Ein endgültiges Urteil wird nach umfangreichen Überlegungen innerhalb von zwei bis drei Monaten erwartet. CBIH betont, dass die Neu-Klassifizierung eine verantwortungsvolle medizinische Nutzung ermöglichen und langanhaltende rechtliche Unklarheiten klären würde.
Positive
Negative
12/02/2024 – 08:00 AM
HOUSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) — Cannabis Bioscience International Holdings (OTCMKTS: CBIH) proudly announces its active participation in today’s DEA meaningful hearing on cannabis reclassification. Representing CBIH at this critical event in Arlington, Virginia, is Dante Picazo, the company’s esteemed Director and CEO, bringing years of expertise and leadership in the medical cannabis industry to Docket No. 1362, Hearing Docket No. 24-44.
Mr. Picazo has presented a comprehensive 78-page statement that underscores the advantages of reclassification and addresses the profound limitations of its current designation as a Schedule I substance (CBIH CORE ARGUMENTS).
“This could be the culmination of a 50-year struggle to bridge the gap between science, policy, and opportunity,” said John Jones, CBIH Treasurer and Director. “The stakes could not be higher. The profound disadvantages of prohibition extend beyond individual lives, we have seen decades of lost economic opportunities, missed investments, unrealized job creation, and a thriving illegal market that could have been transformed into a well-regulated industry. Reclassifying cannabis is not just a moral imperative; it is a legal, economic and scientific necessity.”
“This will be an intense and fiercely challenging event, a grueling battle of perspectives that demands perseverance and determination. Over the course of the next two to three months, a final verdict could be reached after extensive deliberation and debate. There will be participants advocating for the reclassification, as well as legal professionals who will oppose it. They will present their most compelling arguments in this historic forum. For those who believe in the reclassification of cannabis in the United States, this is not a time for complacency; it is a call to action. Change will not come without resistance, and we must stand together in this vital mission,” adds Mr. Jones.
“This is about ensuring the freedom for responsible medical use while resolving decades of ambiguity” emphasized Dante Picazo, CBIH Director and CEO. “For far too long, thousands have been incarcerated for merely possessing a plant that humanity has relied upon for centuries. Reclassifying cannabis represents a long-overdue moment in history, comparable in cultural and societal impact to the fall of the Berlin Wall in 1989—an event that ended an era of division, reunited families, and unlocked significant economic opportunities. This metaphor reflects the walls created by the prohibition of cannabis: the Schedule I of cannabis has led to the separation of families and denied patients life-saving treatments. As cancer remains an incurable disease in 2024, it continues to cause immense grief for families. However, cannabis presents hope, with compounds that have demonstrated the ability to target tumors and preserve healthy tissue, offering a safer alternative to chemotherapy’s damaging effects and advancing medical research. The urgency to reclassify its legal status cannot be overstated. It is time to dismantle these barriers and move forward. Why delay the inevitable?” adds Mr. Picazo.
CBIH supports the reclassification of Cannabis and envisions a future where individuals can access medicinal cannabis without the threat of legal repercussions. This new paradigm would not only improve patient care but also stimulate economic growth by fostering a dynamic industry, creating jobs, attracting investment, and advancing scientific research. Universities would incorporate cannabis-related programs and degrees, driving innovation and expanding knowledge, while facilitating legal, safe access to medicinal cannabis and promoting its role in modern healthcare.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words “believe,” “expect,” “should,” “intend,” “estimate,” “projects,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company’s current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company’s filings, which are on file at www.OTCmarkets.com.
For more information contact us at:(214) 733-0868ir@cbih.netDante PicazoCEO – CBIHWebsite: www.cbih.netX: www.twitter.com/cbihstockInstagram: www.instagram.com/CBIHSTOCK
When did CBIH participate in the DEA cannabis reclassification hearing?
CBIH participated in the DEA cannabis reclassification hearing on December 2, 2024, in Arlington, Virginia.
What is the expected timeline for the DEA’s decision on cannabis reclassification according to CBIH?
According to CBIH, a final verdict on cannabis reclassification is expected within two to three months after extensive deliberation and debate.
What document did CBIH’s CEO present at the DEA hearing?
CBIH’s CEO Dante Picazo presented a comprehensive 78-page statement addressing the advantages of reclassification and the limitations of cannabis’s current Schedule I designation.
“}]] Cannabis Bioscience International Holdings presents comprehensive case for cannabis rescheduling at DEA hearing, highlighting medical research and economic potential. Read More
